Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event
Sarepta said this morning that it has halted dosing its Duchenne muscular dystrophy drug golodirsen at all its UK sites after one of the patients in the trial experienced an adverse event. But the biotech swiftly indicated that it doesn’t expect the halt to last for long.
The news was first reported by EP Vantage writer Jacob Plieth, who noted chatter about the dosing halt on Facebook citing issues with rhabdomyolysis side effects — a breakdown of muscle tissue that triggers severe pain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
